𝔖 Bobbio Scriptorium
✦   LIBER   ✦

864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study

✍ Scribed by R.P. Abratt; D. Brune; M.A. Dimopoulos; J. Kliment; J. Breza; P. Selvaggi; P. Beuzeboc; T. Demkow; S. Oudard


Book ID
118621030
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
167 KB
Volume
1
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.